Posts

Posted on

GOGL – Transactions made under the buy-back programme

Reference is made to the stock announcement on October 4, 2022, where Golden Ocean Group Limited (OSE/NASDAQ: GOGL) announced the commencement of its share buy-back programme of maximum USD 100 million to purchase up to an aggregate of 10,000,000 of the company’s common shares in a 12 months period from the announcement.

Golden Ocean Group Limited (“GOGL” or the “Company”) announces that the Company has on December 2, 2022, purchased 250,000 of the Company’s own common stocks. 100,000 of the shares have been bought on the Oslo Stock Exchange at an average price of NOK 79.37 per share and 150,000 of the shares have been bought on Nasdaq at an average price of USD 8.20 per share. Following the completion of the above transactions, GOGL owns a total of 555,000 of own shares, corresponding to 0.28% of the Company’s share capital.

An overview of all transactions made under the buy-back programme that have been carried out during the above-mentioned date is attached to this report and available at www.newsweb.no.

December 5, 2022
Hamilton, Bermuda

For more info please contact:

Peder Simonsen, Chief Financial Officer of Golden Ocean Management AS.
Telephone +47 23 11 40 00

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

Forward-looking statements: This release and any materials distributed in connection with this release may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Attachments



Posted on

MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases

Curamys to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to help advance its cell fusion technology.

ROCKVILLE, Md. and SEOUL, South Korea, Dec. 04, 2022 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Curamys, a South Korean biotechnology company that develops cell & gene therapy using cell fusion technology to treat rare intractable diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, today announced the signing of a strategic platform license (SPL).

Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.

Curamys is focused on developing treatments for genetic and degenerative diseases through its specialized cell fusion technology, based on the concept that apoptotic or dying cells can be regenerated by fusing them with healthy normal cells. Cell fusion technology can function as a form of gene therapy when the normal copies of genes existing in treatment cells are transferred to dying cells, resulting in the development of a treatments for genetic and rare intractable diseases at the cellular level.

“A recent report estimates that there are more than 10,000 distinct rare diseases affecting 400 million people around the world,” said Doug Doerfler, President and CEO of MaxCyte. “Many of these diseases, like ALS and DMD, have few or no treatments. We are honored to support Curamys’ efforts to develop its cell-fusion technology for novel cell-based treatments that provide hope and new options to patients and their families.”

“At Curamys, our goal is to use cell fusion-based technologies to transform the biomedical sciences by helping to identify genetic factors contributing to numerous rare diseases with unknown medical causes,” said Dr. Jung Joon Sung, CEO of Curamys. “MaxCyte’s Platform will enable us to advance this technology so we can expand our global reach and ultimately, help more patients living with rare diseases.”

MaxCyte’s ExPERT™ instrument portfolio is the next generation of leading, clinically-validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Curamys is MaxCyte’s 18th SPL overall, which generate pre-commercial milestone revenue and the vast majority of which include post-commercial revenue.

About MaxCyte

MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® technology, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.

About Curamys

Curamys is a biotechnology company that develops cell & gene therapeutics intended to offer treatment for rare intractable diseases. The company’s platform uses cell fusion technology – a novel approach that allows the healthiest and youngest cells to find apoptotic (diseased or dying) cells and fuse together so the apoptotic cells can heal. This technology can be combined with stem cell therapy to develop a therapeutic agent, and it can be used for finding the causes of intractable diseases at the cellular level enabling healthcare professionals to treat certain rare genetic diseases. Currently, Curamys is devoted to develop therapeutics for the treatment of rare diseases, including Duchenne muscular dystrophy, Lou Gehrig’s disease (i.e., amyotrophic lateral sclerosis), and nonketotic hyperglycinemia. Learn more at curamys.com.

MaxCyte Contacts:


US IR Adviser



Gilmartin Group


David Deuchler, CFA
+1 415-937-5400
[email protected]


US Media Relations



Spectrum Seismic Collaborative


Valerie Enes
+1 408-497-8568
[email protected]


Nominated Adviser and Joint Corporate Broker


Panmure Gordon

Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500


UK IR Adviser



Consilium Strategic Communications


Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
[email protected]

Curamys Contact

David Lee, CDO
[email protected]



Posted on

CGG Announces New Integrated Multi-Client Data Project in Southeast Arizona to Support Mining Industry

Paris, France
–
December
5
, 2022

CGG, a global technology and Earth sciences leader, has announced a new multi-client data project in Southeast Arizona focusing on exploration and development in the mining industry. The project, supported by industry funding and available to license now, will begin immediately, with final products scheduled for delivery through CGG’s proprietary GeoVerse™ platform.

Dechun Lin, EVP, Earth Data, CGG, said: “Our Southeast Arizona data project represents a significant step forward in our strategy to provide integrated data solutions for the mining industryand is an innovative and effective model to improve data access in critical mining regions.”

As part of this project, CGG will acquire over 270,000 line-kilometers of new airborne multi-physics data, including aeromagnetic, radiometric and airborne gravity data. CGG’s extensive team of subsurface experts and data scientists will integrate this data set with 50,000 km2 of satellite imagery, multispectral data, and all available data from a broad spectrum of wells and geological data sources, to deliver a single comprehensive, consistent and cross-disciplinary data set to support innovative methods of exploration.

For more info about CGG’s Southeast Arizona multi-client project, contact: [email protected]

About CGG

CGG (

www.cgg.com

)
is a global technology and HPC leader that provides data, products, services and solutions in Earth science, data science, sensing and monitoring. Our unique portfolio supports our clients in efficiently and responsibly solving complex digital, energy transition, natural resource, environmental, and infrastructure challenges for a more sustainable future. CGG employs around 3,300 people worldwide
and
is listed on the Euronext Paris SA (ISIN: 0013181864).

Contacts

Group Communications & Investor Relations

Christophe Barnini
Tel: + 33 1 64 47 38 11
E-Mail: [email protected]

 

 

 

Attachment



Posted on

Golar LNG Limited – Contemplated buy-back of bonds

5 December 2022

Golar LNG Limited (“Golar“) announces an offer to buy-back parts of its USD 300,000,000 senior unsecured bonds maturing 20 October 2025 (with ISIN NO 0011123432) for cash (the “Buy-Back Offer“).

DNB Markets (the “Manager“) is acting as manager of the Buy-Back Offer. The Buy-Back Offer will be conducted as a “Reverse Dutch Auction”, where bondholders can offer bonds, at desired volumes and prices, to Golar, through the Manager. Golar reserves the right to accept any volume up to an accepted price, or to reject all received offers. 

All bondholders, subject to legal constraints (if any) are hereby invited to provide offers for sale of all or a portion of their bonds through submission of the attached bondholders offer form (the “Bondholders Offer Form“). The final date for submission is 16:00 CET, 9 December 2022. On or prior to 09:00 CET on 12 December 2022, Golar will decide upon the highest buy-back price (the “Buy-Back Price“) acceptable and consequently the total amount of bonds to be repurchased, if any.

All bondholders with offers equaling the Buy-Back Price or lower will receive the Buy-Back Price (plus accrued interest) on allocated amounts up to the amounts offered within the accepted maximum price. Golar may in its sole discretion reduce the number of Bonds to be acquired on a pro rata basis for Bonds offered at the Buy-Back Price. Cash settlement is set to 15 December 2022.

In the attached Bondholder’s Offer Form further details and restrictions related to the offer is stated. Each bondholder must on its own consider if it is covered by any restrictions that hinders it from participating in the offer.

All submissions of Bondholders Offer Form must be sent by e-mail to DNB Markets no later than 16:00 CET, 9 December 2022. Contact details:

DNB Markets Credit Sales by tel: +47 24 16 90 30; or
DNB Markets, Bond Syndicate by e-mail: [email protected] 

Golar may, in its sole discretion, waive, extend, terminate or withdraw the size of the buy‑back at any time. Any prospective changes to this offer will be announced on www.stamdata.com.

Please see Bondholders Offer Form attached.

Enquiries:

Golar Management Limited: + 44 207 063 7900
Karl Fredrik Staubo – CEO
Eduardo Maranhão – CFO
Stuart Buchanan – Head of Investor Relations

Important information:

The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Canada or Japan (including its territories and possessions) or in any other jurisdiction where such publication or distribution is unlawful.

This release is an announcement issued pursuant to legal information obligations and is subject of the disclosure requirements pursuant to the Market Abuse Regulation (MAR) Article 17 no. 1 and section 5-12 of the Norwegian Securities Trading Act, and was prepared by Stuart Buchanan, Head of Investor Relations at Golar LNG Limited, tel. +44 20 7063 7900. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended) which reflects management’s current expectations, estimates and projections about its operations. All statements, other than statements of historical facts, that address activities and events that will, should, could or may occur in the future are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “expect,” “plan,” “anticipate,” “intend,” “forecast,” “believe,” “estimate,” “predict,” “propose,” “potential,” “continue,” or the negative of these terms and similar expressions are intended to identify such forward-looking statements.

These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Golar LNG Limited undertakes no obligation to update publicly any forward-looking statements whether as a result of new information, future events or otherwise, unless required by applicable law.

Attachment



Posted on

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

– TXMD to receive approximately $153.1 million in consideration at closing (including approximately $13.1 million for acquired net working capital), up to approximately $42.6 million in minimum royalty payments, and up to $30.0 million in additional milestone payments –

– Mayne Pharma gains exclusive U.S. commercialization rights for TXMD’s products –

– Transaction allows TXMD to recapitalize and transform into a pharmaceutical royalty company –

BOCA RATON, Fla.–(BUSINESS WIRE)–
TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited (“Mayne Pharma”), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States. In addition, TXMD has agreed to sell certain assets to Mayne Pharma to allow Mayne Pharma to commercialize the products.

At closing of the transaction, TXMD will receive an upfront cash payment of $140.0 million for the license grant and sale of certain assets, plus an additional approximately $13.1 million, subject to customary adjustments, for acquired net working capital. In addition, TXMD will receive a 20-year royalty stream tied to Mayne Pharma’s net sales of the products. The upfront payment to be made by Mayne Pharma, along with cash on hand, will allow TXMD to repay its outstanding indebtedness with Sixth Street Partners and to redeem its outstanding preferred equity, with TXMD continuing as a pharmaceutical royalty company with the potential to create value for stakeholders over time from the resulting net cash flows.

“After completing a thorough evaluation of several strategic alternatives, our Board of Directors concluded that this transaction with Mayne Pharma would create the most value for TherapeuticsMD’s stakeholders,” said The Honorable Tommy Thompson, Executive Chairman of TherapeuticsMD. “This transaction will allow us to repay in full our debt to Sixth Street Partners and redeem our preferred stock from Rubric Capital Management, while also establishing a future royalty revenue stream for our common shareholders. We believe that Mayne Pharma has the experience necessary to fully realize the promise of our products as we work together to improve patient care.”

Transaction Details

Under the terms of the transaction, TXMD will grant Mayne Pharma an exclusive license to commercialize the Company’s Imvexxy®, Bijuva®, and its prescription prenatal vitamin products sold under the BocaGreenMD® and vitaMedMD® brands and will assign to Mayne Pharma the Company’s exclusive license to commercialize Annovera® (collectively, the “Products”) in the United States. In addition, TXMD will sell to Mayne Pharma certain assets to allow Mayne Pharma to commercialize the Products, including inventory.

Upon completion of the transaction, which is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Act of 1976, Mayne Pharma will be responsible for development, regulatory filings, manufacturing, and commercialization of the Products.

TXMD will receive an upfront payment of $140.0 million for the sale of the assets and the grant of the licenses, plus a payment of approximately $13.1 million for the acquisition of net working capital, subject to certain customary adjustments.

In addition, Mayne Pharma will make one-time, milestone payments to the Company of (i) $5.0 million if aggregate net sales of all Products in the United States during a calendar year reach $100.0 million, (ii) $10.0 million if aggregate net sales of all Products in the United States during a calendar year reach $200.0 million and (iii) $15.0 million if aggregate net sales of all Products in the United States during a calendar year reach $300.0 million. Further, Mayne Pharma will pay to the Company royalties on net sales of all licensed Products in the United States at a royalty rate of 8.0% on the first $80.0 million in annual net sales and 7.5% on annual net sales above $80.0 million, subject to certain adjustments, for a period of 20 years following the closing. The royalty rate will decrease to 2.0% on a Product-by-Product basis upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version of a Product launching in the United States. Mayne Pharma will pay to the Company minimal annual royalties of $3.0 million per year for 12 years, adjusted for inflation at an annual rate of 3%, subject to certain further adjustments (cumulative ~$42.6 million).

In connection with entering into the transaction, the lenders and administrative agent under the Company’s Financing Agreement with Sixth Street Partners have agreed to extend the maturity date of the Financing Agreement to December 31, 2022, allowing the Company to complete the transaction with Mayne Pharma on or before that date. The maturity date of the Financing Agreement may be further extended to January 31, 2023, upon payment of an amendment fee, in the event the definitive agreements in connection with the transaction remain in effect and the waiting period under the HSR Act has not expired or terminated.

The Company will retain its existing licensing agreements with Knight Therapeutics, Inc. and Theramex HQ UK Limited.

The transaction is not subject to any financing conditions and is expected to close at the end of 2022, pending satisfaction of customary closing conditions.

Advisors

Greenhill & Co., LLC is serving as financial advisor and DLA Piper LLP (US) is serving as legal counsel to TherapeuticsMD.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. TherapeuticsMD’s products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. TherapeuticsMD is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit https://www.therapeuticsmd.com/ or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

Cautionary Notes Regarding Forward Looking Statements

Certain statements in this communication, including, without limitation, statements regarding the proposed transaction, expectations with regard to the financial impact of such transaction on the Company, future potential milestone and royalty payments, plans and objectives, and management’s beliefs, expectations or opinions, may contain forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and often address expected future actions and expected future business and financial performance. Forward-looking statements may be identified by the use of words such as “believe,” “will,” “should,” “estimate,” “anticipate”, “potential,” “expect,” “intend,” “plan,” “may,” “subject to,” “continues,” “if” and similar words and phrases. These forward-looking statements are not guarantees of future events and involve risks, uncertainties and assumptions that are difficult to predict.

Actual results, developments and business decisions may differ materially from those expressed or implied in any forward-looking statements as a result of numerous factors, risks and uncertainties over which the Company has no control. These factors, risks and uncertainties include, but are not limited to, the following: (1) the conditions to the completion of the proposed transaction may not be satisfied, and the possibility that if the agreements with Mayne Pharma are terminated, it will constitute an event of default under the Company’s Financing Agreement and the Company may not continue as a going concern; (2) the parties’ ability to complete the proposed transaction in the anticipated timeframe or at all; (3) the occurrence of any event, change or other circumstance that could give rise to the termination of the agreements between the parties to the proposed transaction (including that if the agreements are terminated it is an event of default under the Company’s Financing Agreement and the Company may not continue as a going concern); (4) the effect of the announcement or pendency of the proposed transaction on business relationships, operating results, and business generally; (5) risks that the proposed transaction disrupts current plans and operations and potential difficulties in employee retention as a result of the proposed transaction; (6) risks related to diverting management’s attention from ongoing business operations; (7) the outcome of any legal proceedings that may be instituted related to the proposed transaction; (8) the amount of the costs, fees, expenses and other charges related to the proposed transaction; (9) the risk that competing offers or acquisition proposals will be made; (10) general economic conditions, particularly those in the life science and medical device industries; (11) stock trading prices, including the impact of the proposed transaction on the Company’s stock price and the corresponding impact that failure to close the proposed transaction would be expected to have on the Company’s stock price, particularly in relation to the Company’s current and future capital needs and its ability to raise additional funds to finance its future operations in the event the proposed transaction does not close; (12) the participation of third parties in the consummation of the proposed transaction; and (13) other factors discussed from time to time in the reports of the Company filed with the Securities and Exchange Commission (the “SEC”), including the risks and uncertainties contained in the sections titled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s most recent Annual Report on Form 10-K, as filed with the SEC on March 23, 2022, and related sections in the Company’s subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, all of which are available free of charge at http://www.sec.gov or under the “Investors & Media” section on the Company’s website at www.therapeuticsmd.com.

Forward-looking statements reflect the views and assumptions of management as of the date of this communication with respect to future events. The Company does not undertake, and hereby disclaims, any obligation, unless required to do so by applicable laws, to update any forward-looking statements as a result of new information, future events or other factors. The inclusion of any statement in this communication does not constitute an admission by the Company or any other person that the events or circumstances described in such statement are material.

Lisa M. Wilson

In-Site Communications, Inc.

212-452-2793

[email protected]

TherapeuticsMD

561-961-1900

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Vitamins/Supplements Medical Supplies Women Fitness & Nutrition Other Health Health Consumer Pharmaceutical General Health

MEDIA:

Posted on

TOP Ships Announces Pricing of $13.5 Million Public Offering

ATHENS, Greece, Dec. 04, 2022 (GLOBE NEWSWIRE) — TOP Ships Inc. (NASDAQ: TOPS) (the “Company”), an international owner and operator of modern, fuel efficient “ECO” tanker vessels, announced today the pricing of a public offering of 6,750,000 units at a price of $2.00 per unit. Each unit consists of one common share and one Class C warrant to purchase one common share, and will immediately separate upon issuance. The gross proceeds of the offering to the Company, before discounts and commissions and estimated offering expenses, are expected to be approximately $13.5 million.

Each Class C warrant is immediately exercisable for one common share at an exercise price of $2.00 per share and will expire five years from issuance. The offering is expected to close on or about December 6, 2022, subject to customary closing conditions.

Maxim Group LLC is acting as the sole placement agent in connection with the offering.

The offering is being conducted pursuant to the Company’s registration statement on Form F-1 (File No. 333-267545) previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”) on December 2, 2022. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Copies of the final prospectus relating to this offering, when available, may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About TOP Ships Inc.

TOP Ships Inc. is an international ship-owning company. For more information about TOP Ships Inc., visit its website: www.topships.org.

Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts.

The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “may,” “should,” “expect” “pending” and similar expressions identify forward-looking statements. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections.

For further information please contact:

Alexandros Tsirikos
Chief Financial Officer
TOP Ships Inc.
Tel: +30 210 812 8107
Email: [email protected] 



Posted on

INVESTOR DEADLINE: Olaplex Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – OLPX

INVESTOR DEADLINE: Olaplex Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – OLPX

SAN DIEGO–(BUSINESS WIRE)–
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Olaplex Holdings, Inc. (NASDAQ: OLPX) common stock pursuant and/or traceable to Olaplex’s initial public offering conducted on or around September 30, 2021 (the “IPO”) have until January 17, 2023 to seek appointment as lead plaintiff of the Olaplex class action lawsuit. Captioned Lilien v. Olaplex Holdings, Inc., No. 22-cv-08395 (C.D. Cal.), the Olaplex class action lawsuit charges Olaplex as well ascertain of its top executives and directors with violations of the Securities Act of 1933.

If you suffered substantial losses and wish to serve as lead plaintiff of the Olaplex class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-olaplex-holdings-inc-class-action-lawsuit-olpx.html

You can also contact attorney J.C. Sanchezof Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].

CASE ALLEGATIONS: Olaplex manufactures and sells hair care products. Pursuant to its IPO, Olaplex issued more than 73 million shares of its common stock to the public at a price of $21.00 per share for approximate proceeds of more than $1.4 billion to Olaplex.

Olaplex purports to participate in the “prestige segment” of the haircare market, which Olaplex claims is “expected to be the fastest growing segment of the global haircare market from 2020 to 2025.” However, as the Olaplex class action lawsuit alleges, the IPO’s offering documents made false and/or misleading statements and/or failed to disclose that: (i) macroeconomic pressures and competition in the haircare market were more robust than Olaplex had represented to investors; (ii) accordingly, Olaplex was unlikely to maintain its sales and revenue momentum; and (iii) as a result, it was unlikely that Olaplex would be able to achieve the financial and operational growth projected in the IPO’s offering documents.

On September 29, 2022, a Piper Sandler analyst downgraded Olaplex to Neutral from Overweight, stating that her work revealed that “competition and misinformation pose growing risks to [Olaplex].” In addition, the analyst indicated that she anticipated investments in marketing and education were needed to offset the headwinds and that “little room for valuation upside given the risks at play.” On this news, Olaplex’s stock price fell by more than 12%.

Then, on October 18, 2022, Olaplex revised its guidance for the 2022 fiscal year. Specifically, Olaplex said it now expects fiscal year 2022 revenue between $704 million and $711 million, significantly down from its prior guidance range of $796 million to $826 million. Olaplex further revealed that Olaplex’s “updated guidance primarily reflects a slowdown in sales momentum that it attributes to macro-economic pressures, increased competitive activity including discounting, and a moderation in new customer acquisition, as well as inventory rebalancing across certain customers which [Olaplex] believes are in response to these same macro-economic pressures.” On this news, Olaplex’s stock price fell an additional 56.7%.

At the time of the filing of the Olaplex class action lawsuit, the price of Olaplex common stock continues to trade below the IPO price of $21.00 per share, damaging investors.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Olaplex pursuant and/or traceable to the IPO to seek appointment as lead plaintiff in the Olaplex class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Olaplex class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Olaplex class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Olaplex class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller is one of the world’s leading complex class action firms representing plaintiffs in securities fraud cases. The Firm is ranked #1 on the 2021 ISS Securities Class Action Services Top 50 Report for recovering nearly $2 billion for investors last year alone – more than triple the amount recovered by any other plaintiffs’ firm. With 200 lawyers in 9 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Attorney advertising.

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices.

Robbins Geller Rudman & Dowd LLP

655 W. Broadway, Suite 1900, San Diego, CA 92101

J.C. Sanchez, 800-449-4900

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

Brookfield Announces Reset Dividend Rate on Its Series 30 and Series 48 Preference Shares

All amounts in Canadian dollars unless otherwise stated.

BROOKFIELD, NEWS, Dec. 02, 2022 (GLOBE NEWSWIRE) — Brookfield (NYSE: BAM, TSX: BAM.A) today announced that it has determined the fixed dividend rate on its Cumulative Class A Preference Shares, Series 30 (“Series 30 Shares”) (TSX: BAM.PR.Z) for the five years commencing January 1, 2023 and ending December 31, 2027, and also determined the fixed dividend on its Cumulative Class A Preference Shares, Series 48 (“Series 48 Shares”) (TSX: BAM.PF.J) for the five years commencing January 1, 2023 and ending December 31, 2027. As previously disclosed, the Series 30 Shares and Series 48 Shares are expected to commence trading on the TSX under the updated symbols “BN.PR.Z” and “BN.PF.J”, respectively, on December 12, 2022.

Series 30 Shares and Series 31 Shares

If declared, the fixed quarterly dividends on the Series 30 Shares during the five years commencing January 1, 2023 will be paid at an annual rate of 6.089% ($0.3805625 per share per quarter).

Holders of Series 30 Shares have the right, at their option, exercisable not later than 5:00 p.m. (Toronto time) on December 16, 2022, to convert all or part of their Series 30 Shares, on a one-for-one basis, into Cumulative Class A Preference Shares, Series 31 (the “Series 31 Shares”), effective December 31, 2022. The quarterly floating rate dividends on the Series 31 Shares will be paid at an annual rate, calculated for each quarter, of 2.96% over the annual yield on three-month Government of Canada treasury bills. The actual quarterly dividend rate in respect of the January 1, 2023 to March 31, 2023 dividend period for the Series 31 Shares will be 1.74896% (7.093% on an annualized basis) and the dividend, if declared, for such dividend period will be $0.43724 per share, payable on March 31, 2023.

Holders of Series 30 Shares are not required to elect to convert all or any part of their Series 30 Shares into Series 31 Shares.

As provided in the share conditions of the Series 30 Shares, (i) if Brookfield determines that there would be fewer than 1,000,000 Series 30 Shares outstanding after December 31, 2022, all remaining Series 30 Shares will be automatically converted into Series 31 Shares on a one-for-one basis effective December 31, 2022; and (ii) if Brookfield determines that there would be fewer than 1,000,000 Series 31 Shares outstanding after December 31, 2022, no Series 30 Shares will be permitted to be converted into Series 31 Shares. There are currently 9,787,090 Series 30 Shares outstanding.

The Toronto Stock Exchange (“TSX”) has conditionally approved the listing of the Series 31 Shares effective upon conversion. Listing of the Series 31 Shares is subject to Brookfield fulfilling all the listing requirements of the TSX.

Series 48 Shares and Series 49 Shares

If declared, the fixed quarterly dividends on the Series 48 Shares during the five years commencing January 1, 2023 will be paid at an annual rate of 6.229% ($0.3893125 per share per quarter).

Holders of Series 48 Shares have the right, at their option, exercisable not later than 5:00 p.m. (Toronto time) on December 16, 2022, to convert all or part of their Series 48 Shares, on a one-for-one basis, into Cumulative Class A Preference Shares, Series 49 (the “Series 49 Shares”), effective December 31, 2022. The quarterly floating rate dividends on the Series 49 Shares will be paid at an annual rate, calculated for each quarter, of 3.10% over the annual yield on three-month Government of Canada treasury bills. The actual quarterly dividend rate in respect of the January 1, 2023 to March 31, 2023 dividend period for the Series 49 Shares will be 1.78348% (7.233% on an annualized basis) and the dividend, if declared, for such dividend period will be $0.44587 per share, payable on March 31, 2022.

Holders of Series 48 Shares are not required to elect to convert all or any part of their Series 48 Shares into Series 49 Shares.

As provided in the share conditions of the Series 48 Shares, (i) if Brookfield determines that there would be fewer than 1,000,000 Series 48 Shares outstanding after December 31, 2022, all remaining Series 48 Shares will be automatically converted into Series 49 Shares on a one-for-one basis effective December 31, 2022; and (ii) if Brookfield determines that there would be fewer than 1,000,000 Series 49 Shares outstanding after December 31, 2022, no Series 48 Shares will be permitted to be converted into Series 49 Shares. There are currently 11,885,972 Series 48 Shares outstanding.

The Toronto Stock Exchange (“TSX”) has conditionally approved the listing of the Series 49 Shares effective upon conversion. Listing of the Series 49 Shares is subject to Brookfield fulfilling all the listing requirements of the TSX.

About Brookfield

Brookfield (NYSE: BAM, TSX: BAM.A) is a leading global alternative asset manager with over US$750 billion of assets under management across real estate, infrastructure, renewable power and transition, private equity and credit. Brookfield owns and operates long-life assets and businesses, many of which form the backbone of the global economy. Utilizing its global reach, access to large-scale capital and operational expertise, Brookfield offers a range of alternative investment products to investors around the world —including public and private pension plans, endowments and foundations, sovereign wealth funds, financial institutions, insurance companies and private wealth investors.

For more information, please visit our website at www.brookfield.comor contact:

Communications & Media

Kerrie McHugh
Tel: (212) 618-3469
Email: [email protected]		 Investor Relations

Linda Northwood Tel: (416) 359-8647
Email: [email protected]

 



Posted on

UNISYS CORPORATION INVESTOR ALERT: Kaplan Fox & Kilshiemer LLP Notifies Unisys Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Unisys Corporation (“Unisys” or the “Company”) (NYSE: UIS). A class action complaint has been filed on behalf of investors that purchased or otherwise acquired Unisys securities between August 3, 2022 and November 7, 2022, inclusive (the “Class Period”).

If you would like to discuss this case or our investigation, please contact us by emailing


[email protected]


or by calling (212) 329-8571. Or click here.

If you are a member of the proposed Class, you may move the court no later than January 10, 2023 to serve as a lead plaintiff for the purported class. If you have losses, we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

On November 8, 2022, Unisys disclosed that it is “is unable to file, without unreasonable effort and expense and within the prescribed time period, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the “Form 10-Q”).

According to the complaint, on November 7, 2022, post-market, Unisys issued a press release disclosing that the Company was lowering its previously stated 2022 financial guidance by a significant margin and that it would be “unable to file, without unreasonable effort and expense and within the prescribed time period, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the ‘Form 10-Q’).”

Specifically, the November 7 press release stated that the Company’s Audit and Finance Committee “is conducting an internal investigation regarding certain disclosure controls and procedures matters” and that “[f]ollowing the evaluation of the results of the investigation, the Company expects that it may determine that there are one or more material weaknesses in its internal control over financial reporting, which may result in a conclusion that the Company’s disclosure controls and procedures and internal control over financial reporting are not effective.”

On November 8, 2022, Unisys shares declined from a closing price on November 7, 2022 of $8.96 per share, to close at $4.58 per share, a decline of $4.38 per share, or over 48%, on very high volume.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

WHY CONTACT KAPLAN FOX – Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.

If you have any questions about this investigation, please contact:

Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(212) 329-8571
E-mail: [email protected]

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax: (415) 772-4707
E-mail: [email protected]



Posted on

Northrop Grumman and the US Air Force Introduce the B-21 Raider, the World’s First Sixth-Generation Aircraft

PALMDALE, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) — Northrop Grumman Corporation (NYSE: NOC) and the U.S. Air Force unveiled the B-21 Raider to the world today. The B-21 joins the nuclear triad as a visible and flexible deterrent designed for the U.S. Air Force to meet its most complex missions.

“The Northrop Grumman team develops and delivers technology that advances science, looks into the future and brings it to the here and now,” said Kathy Warden, chair, chief executive officer and president, Northrop Grumman. “The B-21 Raider defines a new era in technology and strengthens America’s role of delivering peace through deterrence.”

The B-21 Raider forms the backbone of the future for U.S. air power, leading a powerful family of systems that deliver a new era of capability and flexibility through advanced integration of data, sensors and weapons. Its sixth-generation capabilities include stealth, information advantage and open architecture.

“The B-21 Raider is a testament to America’s enduring advantages in ingenuity and innovation. And it’s proof of the Department’s long-term commitment to building advanced capabilities that will fortify America’s ability to deter aggression, today and into the future. Now, strengthening and sustaining U.S. deterrence is at the heart of our National Defense Strategy,” said Secretary of Defense Lloyd J. Austin III. “This bomber was built on a foundation of strong, bipartisan support in Congress. And because of that support, we will soon fly this aircraft, test it and then move into production.”

The B-21 is capable of networking across the battlespace to multiple systems, and into all domains. Supported by a digital ecosystem throughout its lifecycle, the B-21 can quickly evolve through rapid technology upgrades that provide new capabilities to outpace future threats.

“With the B-21, the U.S. Air Force will be able to deter or defeat threats anywhere in the world,” said Tom Jones, corporate vice president and president, Northrop Grumman Aeronautics Systems. “The B-21 exemplifies how Northrop Grumman is leading the industry in digital transformation and digital engineering, ultimately delivering more value to our customers.”

The B-21 Raider is named in honor of the Doolittle Raids of World War II when 80 men, led by Lt. Col. James “Jimmy” Doolittle, and 16 B-25 Mitchell medium bombers set off on a mission that changed the course of World War II. The designation B-21 recognizes the Raider as the first bomber of the 21st century.

Northrop Grumman is a technology company, focused on global security and human discovery. Our pioneering solutions equip our customers with capabilities they need to connect, advance and protect the U.S. and its allies. Driven by a shared purpose to solve our customers’ toughest problems, our 90,000 employees define possible every day.

Credit: Northrop Grumman

Contact:
Katherine Thompson
321-586-8847
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fab2c6e7-f02e-4f5d-a8e3-beaafe0e08cc